SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE:A) today announced that patent infringement litigation claims against Agilent’s microarray, Bioanalyzer and GeneSpring products have been dismissed by Genetic Technologies, Ltd.
No settlement was involved; instead, Genetic Technologies offered to dismiss its claims against Agilent. The parties today filed a mutual dismissal of all claims, in which Genetic Technologies dismissed its patent infringement claims and Agilent dismissed its counterclaims relating to non-infringement and invalidity.
“We are pleased with the outcome of this case,” said Marie Oh Huber, Agilent senior vice president and general counsel. “Agilent has steadfastly asserted that its microarray and other products do not infringe the Genetic Technologies patent. Although Agilent respects valid, enforceable intellectual property rights of others, we will vigorously defend what we believe to be unfounded claims of infringement.”
Genetic Technologies, based in Victoria, Australia, had accused Agilent and other life sciences companies of infringing U.S. Patent No. 5,612,179, titled “Intron Sequence Analysis Method for Detection of Adjacent Locus Alleles as Haplotypes.” Genetic Technologies had asserted that Agilent’s Bioanalyzer, genomic hybridization microarrays and GeneSpring software products had infringed the patent.
Since the inception of the case, Agilent has maintained that none of its products perform the methods claimed in the patent and that no Agilent customer has ever used an Agilent product to perform such methods.
About Agilent Technologies
Agilent Technologies Inc. (NYSE:A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. Agilent generated revenues of $3.9 billion in fiscal 2013. The company employs about 11,000 people worldwide. Information about Agilent is available at www.agilent.com.
NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available on the Agilent news site at www.agilent.com/go/news.